華潤醫藥(03320.HK):建議收購華潤江中的額外權益
格隆匯12月27日丨華潤醫藥(03320.HK)發佈公吿,2023年12月24日,華潤醫藥控股(公司的全資附屬公司)及江西國有資本運營控股(作為買方)(其中包括)與賣方信海潤達訂立股權轉讓協議,據此,賣方已同意透過於江西產權交易所以非公開協議轉讓方式出售華潤江中合共14.4412%權益,其中華潤醫藥控股及江西國有資本運營控股已分別同意購買華潤江中9.2138%及5.2274%的權益(分別相當於華潤江中的註冊資本人民幣2325.95萬元及人民幣1319.62萬元)。
建議收購事項的總代價將為人民幣8.1億元,其中(i)人民幣5.17億元將由華潤醫藥控股用於支付建議收購華潤江中的9.2138%權益;及(ii)人民幣2.93億元將由江西國有資本運營控股用於支付建議收購華潤江中的5.2274%權益。
公吿表示,集團致力加強集團的發展,善用主要營運附屬公司的競爭優勢,冀為公司股東帶來更大價值。透過華潤醫藥控股實施的建議收購事項,公司可從股權及企業管治兩方面有效加強對華潤江中的控制(並藉此加強其對江中藥業的控制),預期將進一步支持華潤江中及其附屬公司的長足發展。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.